Search Results
PSCI 24-076 A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXD) IN SUBJECTS WITH PRETREATED ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) (IDeate-Esophageal01) (A PHASE 3 STUDY OF I-DXD IN SUBJECTS WITH PRETREATED ESCC)
This trial will be examining the use of a drug, ifinatamab in the treatment of patients with advanced or metastatic esophageal squamous cell cancer.
After signing consent, participants will have blood tests and scans to see if they are well enough to participate. If the participate, they will need to come to the clinic to see the study team then get the experimental treatment. Participants will continue treatment until the medication no longer works, they no longer want to participate, or the study doctor feels it is not safe for them to continue.
Has histologically or cytologically documented unresectable locally advanced (Stage II to IVA if T2-T4 or N1-3 M0), or metastatic (Stage IVB) ESCC
Has disease progression post platinum-based and ICI treatment
Has received any topoisomerase inhibitor.
Has histologically or cytologically confirmed adenosquamous carcinoma subtype.
PSCI # 25-038 A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
This trial will examine which combination is better in treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Sorotoclax or Venatoclax.
There are three parts to this study. Screening, when you will meet the study team, sign the consent for and have tests performed to make sure that it is safe for you to participate in the study. If you join the study you will be chosen to participate in one of four arms, each with different medication to treat you disease. During the first cycle of treatment you will need to be seen by the study team between 4 and 7 times, depending upon the treatment. You will continue on the study medication until it no longer works, you have finished the trial or the doctor feels that it is no safe for your to continue ( among other reasons). The third part of the study is follow up. you will have a study visit in the clinic 30 after the last day of taking the study drug. That will be followed by after treatment follow up visits every three months until your cancer returns, if it returns. Then you will be followed every three months to see how you are doing.
Must have confirmed diagnosis of CLL/SLL
Must have received ≥ 1 prior therapy for CLL/SLL
Must not have received any maintenance therapy.
Patients with a history of confirmed progressive multifocal leukoencephalopathy
Prior allogeneic stem cell transplant with active GVHD
Received a live, attenuated vaccine within 4 weeks
A Phase 3, External and Synthetic Placebo-Controlled Randomized Study with Dose-Up for Non-Responders to Investigate Safety and Efficacy of Ritlecitinib 50 mg and 100 mg Once Daily in Adult and Adolescent Participants 12 Years of Age and Older with Alopecia Areata
Alopecia areata (AA) is an autoimmune disease that causes non-scarring hair loss that can be relapsing and chronic. It affects patients of all ages, races, and genders. Symptoms can range from patchy hair loss usually affecting the scalp, to complete scalp hair loss (alopecia universalis) or complete loss of hair on the scalp, face, and body (alopecia totalis). AA has a detrimental impact on patients' emotional wellbeing, self-esteem, social interactions, and quality of life, and psychiatric conditions such as anxiety and depression are more common in patients with AA compared to healthy controls. The purpose of this study is to find out if the study medicine, Ritlecitinib, can help with the treatment of AA.
Study participation will last approximately 57weeks. During the study, participants will attend 9 in person visits in the research office. At different timepoints the participant will have their hair examined, blood drawn, have an ECG and chest x-ray done, have photos taken of their scalp and face, answer questionnaires, and take study medication as directed by the study team.
At least 50% hair loss on the scalp with no regrowth for at least 6 months
Current episode of hair loss no longer than 10 years
Other scalp conditions that could interfere with alopecia assessment
Certain medications are not allowed; study coordinator will discuss
A Community-Based Pickleball Program for Adults with Autism Spectrum Disorder
This study will test whether playing pickleball, a fun and easy-to-learn paddle sport, can improve physical coordination and reduce core autism symptoms in adults with autism spectrum disorder (ASD). Participants will be placed in either an early start group or a delayed start group using a delayed control trial design. The early start group will attend two 90-minute pickleball classes per week for the first 8 weeks and then resume regular activities for the next 8 weeks. The delayed start group will continue regular activities for the first 8 weeks and then transition into the pickleball classes for 8 weeks. All participants will complete pickleball skill assessments at their first and last class to measure improvement, and three testing sessions during the study will assess sensory-motor processing, autism symptoms, mental health, and quality of life. By comparing the two groups, this study aims to determine whether pickleball supports better physical and emotional health for autistic adults and whether it can help participants feel more confident, connected, and engaged in social settings.
Participants will attend two or three in-person testing sessions (baseline, mid-study, and post-study) where they will complete surveys and a videogame-based sensory-motor assessment. They will also participate in two 90-minute coach-led pickleball classes per week for 8 weeks. Pickleball skill assessments will be completed during their first and last pickleball class.
$100
Clinical diagnosis of autism spectrum disorder (ASD)
Able to participate in group activities without caregiver support
Able to understand and communicate in English
Available and able to attend at least two pickleball sessions per week during the 8-week program
Use of mobility aids that limit court-based movement
Moderate-to-severe joint pain
Neurological conditions (e.g., cerebral palsy, epilepsy, severe head injury)
Clinical diagnosis of intellectual disability
Effects of catheter ablation on cardiopulmonary afferents in patients with atrial fibrillation
Catheter ablation for patients with atrial fibrillation (AF ablation) is an effective treatment to improve abnormal heart rhythm (i.e., atrial fibrillation, AF). Autonomic nervous system controls things your body does automatically without thinking, such as regulate heart rate, blood pressure, and respiratory control.It has been reported that AF ablation might improve abnormal autonomic nervous system in patients with AF in addition to improve abnormal heart rhythm. However, the detail is still unclear. In the proposed study, we aim to verify the effect of AF ablation on autonomic nervous system in patients with AF. We will evaluate autonomic nervous system using various approaches in AF patients before and after AF ablation, as well as healthy subjects. The results obtained from this study will provide important insights into the research area of AF treatments.
Patients with atrial fibrillation will have three visits to the research lab with each visit lasting 3-3.5 hours. • Visit 1 (pre-AFib ablation): will occur about 1-2 weeks prior to your procedure • Visit 2: approximately 1 month after your ablation procedure • Visit 3: approximately 3 months after your ablation procedure Patients who are healthy volunteers will ONLY have one visit to the research lab that lasts 3-3.5 hours. Various physiological measurements will be recorded during this time including microneurography, blood pressure, heart rate and blood flow.
You will receive $25 per hour for your participation in this research study
50-85 years of age
Are of any race or ethnicity
Capable of speaking English
Capable of giving informed consent
Incapable of speaking English
Decisional impairment
Age < 50 or > 85 years old
Have any history of chronic diseases including heart failure, severe lung diseases, renal failure, peripheral neuropathy, epilepsy or seizure disorders and other chronic diseases
Platform Wars: Evaluating postural and strength adaptations with Wii Fit Balance vs. Whole-body vibration in college students.
This study will aim to see if there is a difference in strength and balance changes among college students when comparing the Wii Fit Balance and whole-body vibration training.
The study duration will be six-weeks, in which study participants will be involved in either a gaming training group or a vibration platform training group. Participants will complete a baseline session and post-training assessment, each lasting two hours. During both of these visits measures of balance, strength, and walking ability will be acquired. In the six weeks of the study,18 individual vibration or gaming training sessions will be completed. The respective training sessions will take place three times a week for 6 weeks and will last 10-minutes each.
$20.00
Male and female between the ages of 18 and 25.
Known history of musculoskeletal, neurological, cardiovascular, or pulmonary impairment that may affect ability to perform the testing procedures.
Use of a pacemaker.
Major general medical disorders, such as recent surgeries, implants in trained body parts (i.e., artificial joints), acute hernias, discopathies (i.e., slipped disks), rheumatoid arthritis, epilepsy, and/or acute thrombosis.
Using sedatives of any type upon enrollment to the study.
Glycemic Effects of a Mediterranean-Style Dietary Pattern Containing Potatoes in Adults with Prediabetes
The purpose of this research study is to determine if a healthy Mediterranean diet containing one medium potato/day has equivalent or non-different effects on risk factors for type 2 diabetes and heart disease as a healthy Mediterranean diet without potatoes. Participants will be randomly assigned to one of the test diets and be asked to consume this diet for 12 weeks (84 days). Testing will be conducted at the beginning and end of the study.
This study runs for about 3 months. During this time, you will be randomly assigned to one of the test diets and be asked to consume this diet for 12 weeks (84 days). We will provide you with all of the food you need to follow this diet. This will include 3 meals, snacks and some beverages prepared in the Penn State Research Kitchen, which will meet your energy and nutrient needs. During the study, we will ask you not to eat any foods outside of those provided by the study. You may have up to 5 days off the diet during the 12 week period. Testing will take place on two separate days at the beginning and end of the study (4 testing days total). For these visits, you will need to fast for 12 hours prior and avoid alcohol for 48 hours. At these visits, we will collect a blood sample, measure your weight, and perform non-invasive tests to assess your vascular health. You will also be asked to wear a continuous glucose monitor (CGM) for 14 days—7 days before the first testing visit and 7 days at the end of the study. The CGM is a small sensor worn on your arm that measures your blood sugar every 15 minutes. You will need to attend a visit to have the CGM fitted (2 visits total). Additionally, we will ask you to collect a stool sample twice during the study.
500
BMI 25-40 kg/m2
Current use of tobacco-containing products or (≤6 months) cessation
Pregnant or nursing individuals
Allergy to study foods
Alcohol intake > 14 drinks/week
Mechanisms of Action: The Impact of Emotional Well-Being Intervention in Increasing Optimism and Biological Markers
This study aims to support midlife adults by enhancing their emotional well-being and reducing psychological stress, which may affect cardiometabolic health. We are evaluating a novel 4-week program that integrates three components—emotional well-being–enhancing writing, chair-assisted squats, and slow-paced breathing—using a factorial design. Eighty adults aged 40–65 with a sedentary lifestyle will be randomly assigned to one of eight groups that include different combinations of these activities. Participants will engage in their assigned activities via Zoom five times per week over four weeks. Emotional well-being and stress will be assessed through self-report at multiple time points, and physiological health (e.g., blood pressure, heart rate, heart rate variability, inflammation) will be measured during in-person visits before and after the program. The study will also evaluate the feasibility, acceptability, and preliminary effects of each intervention component and their combinations.
Participants will engage in a four-week program involving three components: EWB-enhancing writing exercises, chair assisted squat, and slow-paced breathing. They will complete these activities five times per week, with each session lasting 30 minutes.Participants will undergo cardiovascular assessments at Penn State University’s Biobehavioral Health (BBH) Building at baseline and post-intervention. These assessments will include heart rate variability measured via a standard three-lead electrocardiogram (ECG) and continuous blood pressure measured non-invasively using a finger cuff device that captures beat-to-beat waveforms.
$300
Sedentary lifestyle
Able to engage in chair assisted squat
Willingness to participate in all study components
Ability to provide informed consent
Physical limitations preventing chair assisted squat
Lack of technology or access – no computer/laptop and stable internet for Zoom and Qualtrics participation.
Inability to provide informed consent
Significant medical conditions that could be exacerbated by the intervention (e.g., severe cardiovascular disease)
PSCI# 25-001 TITLE PAGE A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
This study is comparing using rilvegostomig or pembrolizumab with a platinum based chemotherapy. The doctor, subject and study team will not know if the subject is receiving rilvegostomig or pembrolizumab.
After signing consent to agree to join the study, the subject will have lab work and scans of their body to see if they are wll enough to participate. If they begin study treatment, they must come to all study visits. It is important that the subject tell the study team if there has been a change in their medications and how they are feeling. Subjects will continue treatment until the treatment no longer is working, they no longer want to participate of the study doctor feels it is not safe for them to participate any further. Once study treatment is finished, subjects will be followed to see how they are feeling and what new treatments for their cancer they are getting.
$75.00 for each visit completed for a minimum of $300. Compensation may be more if additional visits are completed.
Histologically or cytologically documented squamous NSCLC
Minimum life expectancy of 12 weeks
Minimum body weight of 30 kg.
History of organ transplant
Active or prior documented autoimmune or inflammatory disorders requiring chronic treatment with steroids or other immunosuppressive treatment.
Activate: A Study of Engaged Teaching Methods across college courses
The IRB proposal is to conduct research to enhance effectiveness of teaching and learning in college.
Consent for Exempt Research The Pennsylvania State University Title of Project: A Study of Effective Teaching Methods across College Courses Principal Investigator: Yi-An Burleson, Ph.D. Email: ylb5007@psu.edu You are invited to volunteer to participate in a research study. This summary explains information about this research. The study is to collect data to know ways to improve college teaching and learning. Participants will fill out online surveys in teaching and learning in addition to demographic information (e.g. gender, ethnicity, year of study, etc.). It may take 40-50 minutes to complete all of the questions in the surveys. You are strongly encouraged to take the surveys at the beginning of a semester/quarter/term and then at the end of a semester/quarter/term. You are welcome to take the surveys in more than one semester/quarter/term but no more than twice per semester/quarter/term. There may be mild discomfort in feelings, but no risk beyond mild discomfort is involved in the study. If you feel distressed after taking the surveys, you are encouraged to seek counseling resources at college counseling centers. A list of counseling resources is available on request. Other than your email, no other identifying information will be collected. All of the information you provided will be kept confidential by storing it on password protected devices and two-factor authenticated (2FA) online Drive. You can get access through the Sona system/Study Finder of Penn State University. If you are a student at Pennsylvania State University, you can earn 3 points per course by sending an email to indicate that you in the study (with the name of the study), signing up on the Sona system, and indicate that you consent to participate by, clicking “Yes, I consent to participate. My responses to the following questions indicate that I agree to participate” on top of the Google Form at https://forms.gle/H3p2SnErkhpWmYYm7 and then fill out the online surveys at the end of the consent form. You can fill out the survey in the beginning and end of the semester for multiple semesters. If you have questions, complaints, or concerns about the research, you should contact Yi-An Burleson, Ph.D. at ylb5007@psu.edu. If you have questions regarding your rights as a research subject or concerns regarding your privacy, you may contact the Human Research Protection Program at 814-865-1775. Your participation is voluntary and you may decide to stop at any time. You do not have to answer any questions that you do not want to answer.
Students enrolled in a 4-year university
can read and understand English
Participants who are under age 18
Participants who cannot read English
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
This is a Phase 3, randomized, double-blind, placebo-controlled study evaluating the clinical benefit and safety of EFX in subjects with compensated cirrhosis due to NASH/MASH. The study will enroll in 2 cohorts. Cohort 1 will enroll approximately 450 subjects with biopsy-proven compensated cirrhosis due to NASH/MASH. Cohort 2 will enroll approximately 1700 subjects with a clinical diagnosis of compensated cirrhosis due to NASH/MASH.
You will be required to visit the study clinic at specific times points. Laboratory and safety assessments will be completed at each visit. You will need to take the study drug as directed. Study procedures that will be performed include Liver Imaging scans, Liver Stiffness Exams, Electrocardiogram, Bloodwork, Liver Biopsy and an Endoscopy.
Previous history or presence of type 2 diabetes
Body mass index (BMI) ≥ 25.0 kg/m2
Poorly controlled high blood pressure
Any current or prior history of decompensated liver disease
A Phase 2, Multi-Arm, Multi-Cohort, Open-Label Study to Evaluate The Safety a Efficacy of Cretostimogene Grenadenorepvec In Participants With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
The purpose of this Phase 2 clinical trial is to study treating patients with non-muscle invasive bladder cancer (NMIBC) with an investigational drug, Cretostimogene and DDM. Participants will be assigned to either Cohort A or Cohort B depending on whether they have previously been treated with BCG (Bacillus Calmette-Guerin) for NMIBC.
Eligible participants will receive the study drug, Cretostimogene every week for 6 treatments, followed by a maintenance period as directed by the Investigator. For the first 2 years after treatment initiation, participants will be assessed for disease status every 3 months by urine cytology and cystoscopy, with directed TURBT/biopsy (if indicated). CT urogram or MRU will be performed every 6 months. Thereafter, efficacy assessments will be performed at 6-month intervals for up to an additional 2 years
Enhancing Domestic Violence Policies Through the Lens of Public Administration
This dissertation will look at the implementation process of current DV policies/strategies and how the process can be improved in Pennsylvania. The proposal will incorporate the voices of DV survivors and understand their experience with DV services. The goal of the study is to recommend ways to enhance the support structures available to survivors and victims.
Participants will be asked to take part in a one-on-one interview over PSU PSU-licensed Zoom video or audio. The interview will last about 45 to 60 minutes. They will be asked about your experiences with services, any challenges you faced, and your thoughts on what could improve.
20
Must be survivors of domestic violence who have interacted with DV services or the legal system in Pennsylvania within the last five years.
Must be able to provide informed consent
Must no longer be in immediate crisis and have already exited dangerous or abusive situations.
Must know how to speak English.
Currently in an abusive situation
Less than 18 years of age
Not a victim or never used any of the domestic violence services in Pennsylavnia.
Cannto speak or understand English.
PIANO: A Multicenter National Prospective Study of Pregnancy and Neonatal Outcomes in Women with Inflammatory Bowel Disease
The study will investigate the role of standard medications for IBD on pregnancy outcomes. The subjects will be pregnant IBD patients receiving standard therapies. This study will also test whether the IBD medication transferred across placenta predicts the risk of infection. As many women receive these drugs during their reproductive years this information will guide future therapies for women with IBD and their children.
The participants will sign the informed consent. They will complete the questionnaires. There are four to five in the first year of pregnancy. After that, the questionnaires are annual, up to eighteen years after the birth of the child. The participants will have a blood sample done in the second trimester. They will send the sample to the sponsor.
Pregnant
Diagnosed with IBD-Crohn's disease
Receiving active treatment for IBD
Not pregnant
Not able to complete the questionnaires
Validation of Biomechanics Technology in Golf
The purpose of this study is to compare accuracy and repeatability of biomechanical metrics between technologies during golf swings. This study also aims to identify differences in swing characteristics between various skill levels and environments.
You will be screened with a Health History Questionnaire via email, online survey, or in-person. You will come to either the Suzy and Jim Broadhurst Golf Teaching and Research Center (GTRC) or the Penn State Golf Courses with your golf clubs to provide consent, collect blood pressure and heart rate, answer golf-related questions, and perform golf-related tasks (full swing shots with various clubs). Various technologies will be used to measure the biomechanics of your swing. The total time of participation is expected to be about 60-90 minutes.
When you have finished the golf-related activites, you will be provided with a brief piece of instruction from one of the Center’s two Class-A PGA Professionals.
18-55 years old
Physically capable of playing a full round of golf (18 holes)
A known or estimated handicap less than 35 and/or average score less than 120
Healthy and active (> 75 minutes of moderate exercise weekly)
2 or more cardiovascular risk factors according to the Health History Questionnaire
A musculoskeletal injury within the past 3 months
Experiencing pain during a golf swing
Assessing the Human Alignment of Counterfactual Evaluation Metrics in Recourse Generation
This study aims to understand how well current methods for evaluating Counterfactual recourse recommendations match human preferences. Participants will review different Machine learning model generated Counterfactual options and provide feedback on which options they find more practical and feasible. The goal is to improve Counterfactual generation systems so that they can offer recommendations that better align with what people actually want or need.
The participants will attend two Zoom sessions. During each session, they will compare loan profile options and indicate their preferences and acceptable change limits. A researcher will record their responses in the survey form. Each session will last approximately 30–45 minutes. Participants will receive $10 for completing the first session and $15 for completing the second session.
25
able to communicate in English
have access to a device with Zoom capability
willing to attend two 30–45 minute Zoom sessions
cannot provide informed consent
without access to the internet or Zoom
Driver Situation Awareness in Automated Driving Systems
This research is being done to investigate the effect of human-machine interface design on promoting driver situation awareness restoration and effective human-AI collaboration under varied takeover situations.
You will complete a set of questionnaires and evaluate the design of the automated driving system by driving on a driving simulator. During the drive, you will be asked to drive in automated mode and focus on tasks unrelated to driving until the system issues a takeover request. The form of the takeover request will change in the experiment. You will be wearing eye tracking glasses while performing the driving task. After the driving tasks, you will complete questionnaires about your perception of the system.
$10/hour
Fluent in English
Age 18 or older
Normal vision or vision that is corrected with contact lenses
Ready Set Recharge! Pilot Study
The objective of this study is to pilot test a text-message and electronic delivered educational intervention, Ready, Set Recharge focused on the mental health benefits of physical activity ( PA) in undergraduate students at Penn State University.
Participants interested in participating in this study will be directed to complete a pre-program survey that will take less than 30 minutes to complete. After completion of the survey, participants will be enrolled in the program which is 8 weeks in duration. The program is entirely online and participants will be sent weekly text messages with links to content to read about physical activity and mental health. Participants will also be taught strategies they can try to increase their physical activity behavior in their own life. Participants will compete weekly surveys that take less than 5 minutes to complete. At the end of the 8-weeks, participants will complete a post-program survey that will take less than 30 minutes to complete.
$25
Can read and understand English
18 years of age or older
Unable to read or understand English
Under the age of 18
PSCI 23-130 RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
This trial is looking at the progression free survival and overall survival in patients treated with docetaxel alone and those treated with docetaxel and RAS G12X-C
This study has 4 periods: 1. Pre-screening period (to provide your tumor genetic information) 2. Screening period (before you begin the study to see if you qualify for the study). This is when you will have all the testing done to make sure it is safe for you to join the study. it may require several trips to the hospital. 3. Study Treatment period (when you will receive the study treatment; this occurs in 21-day cycles). this is when you will be taking the study medication. For the first cycle of treatment you will need to come to the clinic about 3 times to make sure you are ok while taking the study drug. From cycle 2 onward you will need to come to the clinic twice. 4. Follow-up period (to check on you after your study treatment is finished) and then we will check to see how you are doing every three months. It is important that you come to all of your visits.
Histologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy.
Evidence of progressive disease (PD)
Chemotherapy and Antibody Therapy; ≥3 weeks of randomization
Symptomatic congestive heart failure
The effect of input conditions on language learning: The roles of salience, modality and context.
The present study will examine the role of different input conditions on the learning of words and morphosyntactic units in a new language. We specifically aim to examine the effects of variables researched in the field: type of knowledge (explicitly stated via pre-training, or incidental; Pellicer-Sánchez et al., 2021), salience (manipulated via input properties; Ellis & Sagarra, 2010) and modality (visual or auditory; Borro, 2021) play on learning outcomes. Our goal is to examine how cognitive processes underlying learning are affected by our manipulations, and the impact on learning outcomes. We hypothesize that pre-training will enhance speakers' ability to detect target vocabulary and structures to be learned. While the literature is mixed on the role of salience, across the experiments described below, we will explore the impact of low-level salience (e.g., text enhanced visually) and psychological salience (the amount of repetition / expectedness of a target items. We will also investigate the less investigated effect of modality.
This is a language learning study. There will be up to two visits to the research lab. Sessions will consist of simple tasks consisting of readings sentences, remembering words, and completing memory tasks. EEG data will be collected via a wearable EEG cap; eye-tracking data will be collected while reading and completing some of the tasks are on a computer.
18 / hour
Must be between 18 and 45 years old.
Right handed
Normal or corrected-to-normal vision
No history of neurological disorders or language disorders, or current condition requiring psychoactive medication (e.g. antidepressants, antianxiety medications, ADHD stimulants, etc.)
Speakers with low English proficiency.
Left-handed or ambidextrous
Uncorrected vision
A history of neurological disorders or language disorders, or current condition requiring psychoactive medication (e.g. antidepressants, antianxiety medications, ADHD stimulants, etc.)
A Phase 1 Single and Multiple Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants with Hemophilia A or Hemophilia B (Part B)
SR604 is a monoclonal antibody that blocks anticoagulant activity, which improves clotting in patients with the clotting disorders of Hemophilia A & B. This study is looking at treatment options for Hemophilia A & B. There will be 4 cohorts (1B, 2B, 3B & 4B). Our site will be starting study drug SR604 dose escalation with 0.1mg/kg (2B), then 0.2mg/kg (3B) with the final dose 0.4mg/kg (4B). Lower doses will start in the first cohort & dose escalation will continue in subsequent cohorts after a 3-month monitoring period in each cohort. See page 44 of the protocol for patient numbers in each cohort.
Participants will receive subcutaneous SR604 every 4 weeks for 3 months. Total visits to site will be 15. Blood draws will be obtained at each of these 15 visits.
75.00 per visit travel reimbursement
Severe congenital Hemophilia A
Severe and/or moderate congenital Hemophilia BA
Patients with inhibitors are permitted
Hemophilia A pts. currently treated with hemlibra
Active infections requiring antibiotic/antiviral therapy
Menopause Stage and Depression Symptomatology
This study aims to examine differences in physiological variables (inflammation and heart rate variability) at different menopausal stages and whether these differences influence depression symptomatology. There will be one 3.5-4 hour in person study visit that includes completion of questionnaires, cognitive tests, electrocardiogram (ECG) recordings, and one blood draw.
There will be one 3.5-4 hour in person study visit that includes completion of questionnaires, cognitive tests, electrocardiogram (ECG) recordings, and one blood draw. If you are in the early perimenopausal/late reproductive group and still having menstrual periods, you will be asked to record menstrual bleeding on a menstrual calendar for 3 cycles.
75
assigned female at birth
English fluent
less then 2 years past the final menstrual period if postmenopausal
if on antidepressants, on a stable dose for 8 weeks
taking hormone medications in past 3 months
on strong anti-inflammatory medications
history of cardiovascular (other than hypertension) or neurological disease
Diagnosis of Bipolar or Psychotic Disorder
Producing code-switched speech
Bilinguals frequently mix languages, even mid-sentence, when communicating with other bilinguals, a practice known as code-switching. This study aims to understand how bilinguals weave together different ways of producing the same sounds, corresponding to the languages they use, when code-switching. Participants will read aloud a list of sentences in Spanish, or in Spanish with switches to English partway through. They will also complete English and Spanish proficiency tasks and a questionnaire about their language background.
Participants will participate in a single session in our lab, lasting about an hour. During this time participants will: Produce words and sentences in Spanish and English. These will be audio recorded. Read and make decisions about words in Spanish and English. Name pictures in Spanish and English. These will be audio recorded. Complete a questionnaire about your language background.
$15
Speaker of Puerto Rican Spanish
A Clinical Investigation of the Adjustable Continence Therapy (ACT) for Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
The purpose of this study is to find out if an implant of ACT is safe and effective in reducing urinary incontinence. The study will involve about 132 women that have urinary incontinence. This system is investigational. After placement of the devices, participants will be followed for 12 months on a regular visit schedule. Annual visits may continue for up to 5 year. ACT® is an implantable device for treating stress urinary incontinence. One end of the device is a balloon that is attached by a tube to a port at the other end of the device.
Participants will attend a screening visit, the implantation visit, post-op assessment, 6 week, 3 month, 6 month, 12 month, and annual follow up visits for necessary device adjustments.
600
Failed at least 6 months of previous treatment for stress urinary incontinence
Currently undersoing radiation therapy
Pregnant/lactating women
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) with Low-Dose Post-Transplant Cyclophosphamide for Prophylaxis of Graft-versus-Host Disease in Hematological Malignancies
This study is testing whether a lower dose of a medicine called cyclophosphamide (25 mg per kg), given after an allogeneic stem cell transplant, can reduce serious side effects and improve outcomes. We are enrolling people who are receiving a reduced-intensity or non-myeloablative (less intensive) stem cell transplant. We will follow participants for one year after their transplant to see if they stay free from severe graft-versus-host disease (GVHD), cancer relapse, or death. We will also look at overall survival, rates of GVHD, infections, donor cell recovery, and other side effects.
You must attend all scheduled study visits, tell the study doctor about all medications you are taking (including over-the-counter medicines), and let the study team know how you are feeling. Before joining the study, you will have routine health checks. These include breathing tests (called pulmonary function tests, or PFTs) to see how well your lungs work, and a heart scan (MUGA scan or echocardiogram) to see how well your heart is pumping. As part of this study, you will be given a low dose of cyclophosphamide (25 mg/kg) on day +3 and +4 after your stem cell transplant. You will be carefully monitored for any side effects, and the study team will evaluate your risk for graft-versus-host disease (GVHD) and disease relapse.
Patients with acute leukemia (acute myeloid leukemia, acute lymphoblastic leukemia, mixed phenotype acute leukemia) or chronic myeloid leukemia with no circulating blasts and less than 5% blasts in the bone marrow.
Patients with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia with no circulating blasts and less than 10% blasts in the bone marrow (exception allowed due to lack of difference in outcomes with <5% vs 5-10% blasts in this disease).
Patients with secondary acute myeloid leukemia progressing from pre-existing myelodysplastic syndrome, myeloproliferative disease (MPN), or MDS/MPN overlap syndrome.
Patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who are indicated for allogeneic stem cell transplantation.
Active central nervous system (CNS) involvement by malignant cells.
Uncontrolled bacterial, viral, or fungal infections (currently taking medication with progression or no clinical improvement).
A Prevention Strategy For The Indication Of Prune Consumption In Perimenopausal Females: Can Prunes Attenuate Bone Loss?
This project will be an 18-month dietary intervention of prune consumption during the late perimenopausal period of the menopause transition investigating if prune intake can slow down the rapid period of bone loss (bone mineral density) that occurs in the late transmenopause. The study will also investigate the effects of prune intake on inflammation, gut permeability, gut microbiome, and bone strength and geometry. Women transitioning into menopause will be randomized to either a group that will consume 6 prunes/day or to a no-prune group that will avoid prunes for the entire duration of the 18-month intervention. Both groups will consume calcium and vitamin D supplements daily. Study procedures will include collection of blood, urine, and stool samples, bone and body composition scans, completion of health-related questionnaires, exercise records, and daily compliance logs.
Participants will be asked to consume calcium and vitamin D supplements daily for 18 months and will be randomized into either a group that will be asked to consume 6 prunes daily for 18 months, or a control group that will be asked to avoid prunes and similar fruits (for example, blueberries, blackberries, pomegranates) for 18 months. There will be 10 in-person visits and 13 virtual visits (Zoom calls). In-person visits include questionnaires, blood draws, and bone and body composition scans. The study also involves urine and stool sampling.
$300
Overall good health
Non-smoking
Ambulatory
At least one episode of no menses of ≥60 days within the past 12 months but no more than 18 months since final menstrual period
Taking hormonal medication or hormonal contraception
Taking medication for osteoporosis
Untreated hypo- or hyperthyroidism
Hyper- or hypoparathyroidism
Circadian Misalignment and Sleep Quality Among Night-Shift Healthcare Workers
This study examines whether night-shift healthcare workers who experience greater differences in their sleep timing between days off and after night shifts also report poorer sleep quality. Participants will complete a brief anonymous online survey about their typical sleep patterns and overall sleep quality.
Complete a one-time anonymous online survey (5-10 minutes) about sleep patterns and sleep quality. Survey includes questions about typical sleep times on days off and after night shifts, plus brief demographics and work information.
Currently employed as a night-shift healthcare worker
Have worked night shifts for at least 3 months
Currently not employed as a night-shift healthcare worker
Less than 3 months of night-shift experience
PSCI# 25-118 A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade
This study is to see if patients with clinical stage I-III HER2+ breast cancer who achieve a pCR after neoadjuvant chemotherapy with HER2 blockade and receive a total of 6 months of HER2 blockade in the combined neoadjuvant + adjuvant (neo/adjuvant) setting will NOT have inferior (RFS) compared to patients who receive the standard total of 1 year of HER2 blockade.
Participants will get the HER2-targeted medication trastuzumab (with or without pertuzumab) for up to 51 weeks (approximately 12 months), or they will get the HER2-targeted medication trastuzumab (with or without pertuzumab) for up to 27 weeks (approximately 6 months). After participant finishes study treatment, your doctor will continue to follow your condition every 6 months for 5 years and watch for side effects or cancer coming back. Participants will see your doctor for 5 years after treatment. After that, every year for a total of 10 years after being enrolled on the study.
has not been naturally postmenopausal for at least 12 consecutive months
Patients (females and males) with clinical stage T1c-T3 (or Tx) and nodal stage N0-N1
Age ≥ 18 years
ECOG Performance Status 0-2
Stage IV (metastatic) breast cancer
History of any prior (ipsi- or contralateral) invasive breast cancer
History of grade 3 or 4 toxicity related to trastuzumab
Usability of a Virtual Reality Laboratory for Sensory Integration
This is a usability study that will evaluate how allied health, education and technology professionals perceive a new virtual therapy environment designed for children with autism spectrum disorder. Participants will experience a guided session using a virtual reality headset. Some participants will experience the VR session with an additional wearable vest that provides gentle vibration feedback, while others will use the VR system without the vest. Assignment to these conditions will be random. After the VR session, participants will complete questionnaires about usability, immersion, and any discomfort. The goal is to improve the tool before it is used in clinical settings.
There will be only one on-site meeting with one hour of duration. Participants will take part in an 25 minutes immersive experience in a virtual environment (with or without a wearable vibration vest, depending on random assignment); and complete one questionnaire before, and four questionnaires after the experience.
$30 Amazon gift card
college degree in one of the following fields: Health, Education, AND/OR Technology
basic knowledge about Autism Spectrum Disorder (ASD), including familiarity with the diagnosis and the ability to identify some common symptoms or characteristics
neurological or vestibular conditions that may be aggravated by immersive virtual reality
pregnancy
experience of nausea, dizziness, or vomiting on the day of the study session
A Pilot Randomized Trial of a Mother-Child Dyadic Positive Affect Prevention Program for Reducing Mental Health Symptoms in Youth Exposed to Deprivation
The purpose of this voluntary research study is to test the effectiveness of the Positive Affect Intervention Program in reducing mental health symptoms for families experiencing financial hardship.
In this study, you and your child will attend some virtual and in-person study visits over 8 months. You will complete some interviews and questionnaires virtually. You will be randomly assigned to either an 8-session prevention program or to receive weekly educational materials to read. You and your child will come to the lab for in-person visits both pre and post program. During these visits, your child will complete some EEG tasks, and you and your child will complete some interaction tasks where your respiratory and heart rate data will be collected. You and your child will also be asked to complete some short daily phone surveys at home.
480 dollars
Child and biological mother can read and speak in English.
Child and mother have access to a computer or tablet with a video camera and internet that can be used for study appointments by Zoom.
Family is experiencing financial hardship.
Children or mothers with intellectual disabilities.
Children or mothers with a diagnosis of mania or bipolar disorder
Children or mothers with a diagnosis of a psychotic disorder (e.g., schizophrenia); or with visual or hearing impairments that interfere with completing study measures and sessions.
Children currently taking psychotropic medications for at least two weeks prior to study participation (except use of stimulant medication which has to be discontinued for 36-hours prior to the EEG visit).